Loading
A phase 3 trial of Pembrolizumab, Sacituzumab tirumotecan, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] is a phase 3 interventional study registered as NCT06422143 by Merck Sharp & Dohme LLC, with 851 participants planned, started 2024-06-10 and due to reach its primary completion in 2029-01-12. Interventions recorded: Pembrolizumab, sac-TMT, Carboplatin, Paclitaxel, Nab-paclitaxel. Conditions listed: Non-small Cell Lung Cancer, NSCLC. No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Platinum agents.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Carboplatin.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Paclitaxel / nab-paclitaxel.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Platinum agents.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Carboplatin.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Paclitaxel / nab-paclitaxel.